Purpose: This study aimed to investigate the prognosis of patients with status epilepticus (SE) following stroke, focusing on the timing of SE after the event and other unexplored variables. Methods: All consecutive patients experiencing post-stroke SE (PSSE) in our center were included (2011)(2012)(2013)(2014)(2015)(2016). We analyzed SE-and stroke-related factors in relation to the patients' outcome. Results: 95 patients with PSSE (54 ischemic and 41 hemorrhagic stroke) were analyzed; 40 were women (42.1%) and mean age was 72.7 ± 13.56 years. 51(53.7%) showed prominent motor symptoms, 49(51.6%) needed > 2 antiepileptic drugs, and 27(28.4%) required anesthetics. Median duration of SE was 12 h (1-240). Median time from stroke to SE was 15 days (0-532). At discharge, logistic regression identified SE within 72 h after stroke (p = 0.004), baseline mSTESS (p = 0.009), and lesion volume (p = 0.001) as independent factors predicting mortality. Female sex (p = 0.019), SE duration > 12 h (p = 0.005), temporal lobe involvement (p = 0.029), and stroke-to-SE time < 90 days (p < 0.0001) were independent predictors of functional decline. At long-term follow-up, SE occurring within 72 h after stroke (p = 0.0001), SE duration (p = 0.004), and baseline mSTESS score (p = 0.012) remained as predictive of mortality. Conclusions: The timing of SE after stroke is associated with different consequences: mortality was higher when SE occurred within the first 72 h after stroke and this risk persisted at follow-up, whereas risk of functional decline was higher when SE occurred during the first 3 months. Other factors such as the mSTESS score and SE duration were associated with outcome at both discharge and long-term follow-up.
Introduction
In status epilepticus (SE), the etiology is a major determinant of the prognosis [1] . Hence, it is essential to investigate each cause of this condition and establish prognostic estimations and therapeutic guidelines accordingly. Cerebrovascular disease is one of the most common causes of SE, and the prevalence of stroke increases with aging. Nonetheless, SE is seldom described in studies reporting post-stroke seizures, and few reports have focused exclusively on post-stroke SE (PSSE).
Convulsive SE has been described in 1% of stroke patients, and SE occurs within the first week following stroke in 0.1% to 0.2% [2] [3] [4] . Nonconvulsive SE has been identified in 3.6% of stroke patients undergoing continuous EEG recording [5] . It is known that patients with stroke and PSSE have a poorer prognosis than those with stroke alone [6, 7] .
Studies specifically addressing PSSE have reported the same risk factors as those defined for single post-stroke seizures: greater neurological deficit, extensive cortical involvement (cortical infarction or lobar bleeding), hemorrhagic transformation, alcohol abuse, sodium imbalance, and involvement of the posterior temporal regions. [4, 5, 8] SE most commonly occurs in the acute phase of stroke rather than as a late complication [2] , and the timing between the 2 events could have prognostic implications. In several related studies, the incidence of SE was higher in the first 2 weeks after stroke, and SE occurring in the acute phase had a poorer prognosis and higher mortality [2, 4, [8] [9] [10] .
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Furthermore, studies investigating mortality in SE patients have reported that cerebrovascular disease is a strong predictor of an unfavorable prognosis and in-hospital mortality [11, 12] .
This differing prognosis was accounted for in the development of the Epidemiology-Based Mortality Score in Status Epilepticus (EMSE). Within the vascular etiologies, the scoring of vascular lesions differs depending on whether the lesion is acute or chronic, with acute lesions yielding a poorer prognosis [13] .
Nonetheless, in studies focused on PSSE, some SE-related variables, such as the duration, treatment, and type on the latest classification [14] , together with certain characteristics of stroke have not been specifically evaluated, and data on the long-term prognosis are scarce. Hence, the aim of this study was to analyze the short-and long-term prognosis of patients with PSSE, with emphasis on the time interval between the 2 events and including these unexplored variables.
Methods
All SE patients older than 16 years seen at our hospital are prospectively recorded in a database that has received approval from our Ethics Committee. For our objective, we included all patients with PSSE attended from February 2011 to March 2016. Patients with unruptured arterial malformations and subarachnoid or subdural hemorrhages were excluded. For SE detection in the acute/subacute phase of stroke, patients were clinically monitored in the stroke unit; if a clinical fluctuation was noted, long EEG recording was added to neuroimaging to rule out a possible SE.
Demographics, baseline functional status using the modified Rankin Scale (mRS), alcohol abuse, and the history of previous seizures were prospectively recorded on admission. The stroke-related variables referred to the index stroke and included the affected territory, the lesion volume determined by computed tomography (CT) at the time of SE and calculated with the standardized AxBxC/2 formula, the type of stroke, the severity according to the National Institute of Health Stroke Scale (NIHSS), and the etiology, using the Trial of org 101172 in acute Stroke Treatment (TOAST) classification.
Classification of SE type was based on the characteristics of the worst clinical seizure in the episode, with retrospective adaptation according to the latest proposed SE classification from the International League Against Epilepsy (ILAE).
14 Episodes with prominent motor symptoms included generalized convulsive SE (GCSE), myoclonic SE, and focal motor SE, whereas episodes without prominent motor symptoms included nonconvulsive SE in coma (NCSEC) and focal (complex partial) SE with or without impaired consciousness. Consciousness level before treatment was categorized as alert, confused (arousable and responsive), stuporous (arousable but non-responsive), or comatose (unarousable). We recorded the time from stroke onset to PSSE onset, the NIHSS score at the time of SE, the type of SE, and the duration. SE was monitored by electroencephalography (EEG) and duration was estimated starting from the time the seizure was clinically diagnosed by a neurologist up to the time EEG monitoring recorded seizure suppression or burst suppression as the target. The modified status epilepticus severity score (mSTESS) was calculated for each patient at admission for SE [15] .
The treatment-related variables covered the treatment lines and number of drugs used, including the use of intravenous anesthetic drugs (IVADs). Refractoriness was established when SE did not resolve after at least 2 lines of treatment were used at appropriate doses.
Complications arising during the SE episode that were not a direct result of the SE etiology were also recorded. These included the development of infectious complications requiring antibiotics (respiratory tract, urinary tract, or bloodstream), severe hemodynamic instability, metabolic disturbances, and respiratory failure.
The clinical outcome was prospectively categorized into 3 groups: return to baseline status, new disability (defined as the development of new neurological impairment and an increase in the mRS score), or death. The latter 2 outcomes were considered indicative of an unfavorable prognosis. Clinical outcome was evaluated at discharge and at latest follow-up.
Statistical methods
Descriptive and frequency statistics were obtained and comparisons made using the SPSS statistical package, version 17.0 for Windows. Statistical significance for intergroup differences was assessed by the Pearson chi-square or Fisher exact text for categorical variables and the Student t or Mann-Whitney U test for continuous variables. Receiver characteristic operator (ROC) curves were configured to calculate cutoff points for the stroke-to-SE time having the best sensitivity and specificity to predict a poor outcome and mortality. Variables found to be associated with a poor outcome and mortality at discharge in the univariate analysis (p < 0.1) were entered into multiple logistic regression models with the forward stepwise method to identify factors independently associated with these outcomes.
Mortality during follow-up was analyzed with the Kaplan-Meier product limit survival method using the log-rank test to determine statistical significance between groups. Continuous variables were assessed with simple Cox proportional hazard models. Variables showing an association (p < 0.1) were entered into a multiple Cox regression model with the forward stepwise method to identify factors independently associated with the mortality rate.
P-values < 0.05 were considered statistically significant.
Results
Among a total of 240 patients experiencing SE and recorded in our registry, 95 patients had PSSE. The mean age of this group was 74 years (23-96 years) and 57.9% (n = 55) were men. Previous epileptic seizures had occurred in 33 patients (34.7%): 5 had acute symptomatic seizures and the remaining 28 were considered to have previous epilepsy; 7 (25%) met the criteria for pharmacoresistant epilepsy. The index stroke was ischemic in 55 (57.9%) patients and hemorrhagic in the remaining ones (42.1%), although half the ischemic strokes (n = 27) showed some type of hemorrhagic transformation. Stroke-related variables are shown in Table 1 .
Based on the ILAE SE classification, 51 (53.7%) episodes occurred with prominent motor symptoms and 44 (46.3%) without prominent motor symptoms (non-convulsive SE). The median duration of SE was 12 h (1-240 hours). Among the 46 patients without drug-refractory SE, 9 responded to benzodiazepines, whereas the remainder required addition of an AED (23 levetiracetam, 5 lacosamide, 5 valproic acid, and 4 phenytoin). Twenty-two patients needed at least 2 AEDs and 27 (28.4%) patients ultimately required therapeutic coma to control SE (Table 1) .
With respect to the timing of SE relative to stroke, 32 (34%) episodes developed within the first 24 h, whereas 39 (41%) occurred at 3 months or later. Among these, 12 took place more than 3 years after the stroke event (Fig. 1) . In 3 patients, SE occurred during an infection (2 urinary and 1 respiratory), but in the rest, no apparent trigger was found. One patient with a late episode and a previous history of seizures was not receiving antiepileptic drugs at the time of SE.
In the assessment of SE outcome at hospital discharge, mortality was 17.9% (n = 17), 46.3% of patients exhibited functional deterioration, and 35.8% had returned to their pre-SE baseline status. After a median follow-up period of 422 days, mortality in the surviving patients was 38.5%, most returned to their baseline status (43.6%), and the remainder (17.9%) continued with functional deterioration (Table 1) .
Before analyzing the prognosis, we examined whether there were differences between ischemic or hemorrhagic stroke. Patients with PSSE after ischemic strokes showed greater neurological involvement (NIHSS, consciousness level, baseline mSTESS), larger lesions, and greater refractoriness (Supplementary Table 1 ). However, there were no differences in the outcome at discharge or at follow-up; hence, the prognosis analysis was performed in the total sample.
Prognosis at discharge
To investigate prognostic factors, univariate analysis was performed of several potentially related variables. With regard to in-hospital mortality (Supplementary Table 2 ), the time interval between stroke and the SE episode was found to be significantly shorter in patients who died (0 days vs. 56 days; p = 0.05). The best calculated cut-off point at which mortality was significantly higher was found to be when SE occurred within 72 h after the stroke event (38.2% vs 5.8%; p = 0.0001). In addition, mortality was greater in patients with a total anterior circulation infarct (TACI) who had higher NIHSS scores both at the time of stroke and at SE onset, and with greater temporal lobe involvement. With regard to the variables specific to SE, lower level of consciousness, lengthier duration of the SE episode, higher mSTESS score, and drugrefractory SE were associated with higher mortality.
On multiple logistic regression analysis, mSTESS score > 4 (p = 0.009), greater lesion volume (p = 0.001), and SE debut within the first 72 h post-stroke (p = 0.004) were found to be independent predictors of in-hospital death ( Table 2 ).
On inclusion of the patients' functional status at discharge in the univariate analysis, the stroke-to-SE temporal cut-off point that marked the difference in the prognosis was 3 months: functional worsening occurred in 91.2% of patients experiencing SE within the first 3 months following stroke and in only 23.9% of those with SE after this time point (p = 0.0001). Other variables related with an unfavorable prognosis on univariate analysis were age, female sex, greater clinical severity (TACI, higher NIHSS score at the index stroke and at SE), and greater temporal lobe involvement (Supplementary Table 3 ). With regard to the SE variables, again, a lower consciousness level, lengthier duration of the episode, higher mSTESS score, and refractoriness were associated with a poorer prognosis.
Following logistic regression analysis, only patient sex (p = 0.019), SE duration > 12 h (p = 0.005), SE debut within the first 3 post-stroke months (p < 0.0001), and temporal lobe involvement (p = 0.029) were independent predictors of a poor functional outcome at discharge in the adjusted model (Table 3 ).
Prognosis at long term
In the long-term follow-up, the relationship between mortality and the stroke-to-SE time persisted: Mortality was significantly higher when SE occurred within the first 72 h following the stroke (p = 0.0001; Fig. 2) . Multiple Cox regression analysis of factors related to mortality Values are expressed as the number (%), unless otherwise indicated. AED, antiepileptic drug; mSTESS, modified status epilepticus severity score; NIHSS, National Institute of Health Stroke Scale; SE, status epilepticus. Table 4 ). This finding suggests that the long-term risk may increase considerably if a shorter time to SE onset is followed by lengthy SE duration (Fig. 3) . Again, on inclusion of the patients' functional status at follow-up, 3 months remained as the stroke-to-SE temporal cut-off point that marked the difference: functional worsening persisted in 76.2% of patients experiencing SE within the first 90 days after stroke compared to 33.3% with SE after this point (p < 0.001). Regression analysis of factors related to a poor functional outcome showed that stroke-to-SE time less than 90 days (OR = 6.890; 95% CI: 2.129-22.298; p = 0.001), age (0R = 1.075; 95% CI: 1.023-1.130; p = 0.005), and sex (0R = 4.630; 95% CI: 1.392-15,398; p = 0.012) were independent predictors of this outcome in the final model (Supplementary Table 5 ).
Discussion
This study, exclusively focused on patients with PSSE, examines the prognosis of this condition in relation to the exact time SE occurs following the stroke event. Our data indicate that SE occurring within 72 h post-stroke is predictive of short-and long-term mortality and SE within 3 months of poor functional outcome. This approach differs from that of the other studies, which only establish a differentiation between acute (usually the first 7 days post-stroke) and later cases. Nonetheless, the data we obtained coincide with these studies in that most PSSE episodes occur in the acute/subacute phase of stroke and that the prognosis of PSSE is related with the time elapsed between the stroke and the onset of SE, with a poorer outcome the earlier SE occurs.
Stroke-to-SE timing
In our series, in-hospital mortality was clearly higher in patients experiencing SE within the first 72 h following stroke. In these cases, it is likely that SE stems from severe injury resulting from an extensive acute lesion, which in itself might explain the higher mortality; in fact, the lesion volume was significantly larger in patients with early SE (Supplementary Table 6 ). It has also been reported that SE and the stroke injury could have a synergistic effect on mortality [7] . In laboratory studies of stroke markers, abnormalities have been described in several pathways (eg, excitotoxicity, inflammation, apoptosis, coagulation) and in gene expression, with a peak of these mechanisms in 24 to 48 h after stroke [16] [17] [18] , when most SE episodes take place. One might consider that overexpression of any of these pathways could occur following SE and contribute to explain the synergistic effect between SE and stroke, and the higher mortality. However, it is difficult to substantiate this concept.
It could be argued that the higher mortality we observed when SE occurred soon after stroke could be related to possible bias in SE detection of more severe cases; that is, some mild, early, nonconvulsive SE episodes may have gone unnoticed. However, all our patients were carefully monitored in the stroke unit, and those with a clinical change that was not fully explained by hemodynamic changes or new findings on neuroimaging reassessment were monitored with EEG. In addition, our findings are in line with the poorer outcome in the early phase of stroke reported in previous studies [2, 4, 9, 10] .
We also found that mortality remained higher over long-term follow-up when SE occurred in the first 72 h following stroke. Most studies reporting high PSSE-related mortality when SE occurs in the acute/subacute phase of stroke do not specify whether the values presented are for in-hospital or long-term mortality [4, 5, 7, 8, 11, 12] .The single study reporting on the long-term outcome by Knake et al [6] does not specifically focus on factors associated with mortality during follow-up. The analysis compares PSSE patients with stroke patients who have not experienced SE; hence, the results are not pertinent to our findings.
In addition to mortality, the poorer prognosis at discharge also included greater functional deterioration when PSSE occurred within the first 3 months. The incidence was similar to the findings of Rumbach et al 2 who reported that approximately 50% of patients with PSSE had functional deterioration following the SE episode, which was temporary in most cases. The authors used a cut-off of 14 days to define acuteonset PSSE but did not clearly specify whether increased neurological decline was related to SE occurring before or after this time point. Other authors [10] investigating PSSE have described post-stroke functional decline as an independent risk factor for developing SE, and found no differences in neurological disability between SE developing during the acute phase (< 7 days) or after. In our series, the risk of functional decline persisted with SE occurring up to 3 months after stroke, not only in the acute phase.
Regarding this aspect, we are aware that SE within 3 months included acute and remote symptomatic episodes, and one might consider this a heterogeneous group. However, we should bear in mind that neurorepair and plasticity mechanisms clearly increase 2-3 days after stroke, and continue to gradually increase over the following weeks and months (during subacute and chronic stages) [18] . The development of SE within the first 3 months may have a harmful effect on these repair mechanisms and explain the higher rate of worsening functional status observed in this time period.
The functional deterioration could also be related to the antiepileptic treatment administered, which could potentially affect neurorehabilitation and neuroplasticity [22] . Nonetheless, this treatment does not exert a substantial clinical effect on the prognosis [23] , and in the present study, the number of antiepileptic drugs given was included in the analysis and no differences were found in this respect.
Regarding the functional outcome at follow-up, PSSE occurring within the first 3 months remained as a factor determining greater deterioration, and this is likely explained by the same reasons discussed above.
Other factors related to mortality
Apart from SE onset in the first 72 h, 2 other factors were independently associated with in-hospital mortality in our analysis. First, the extent of the lesion, a related factor described in both ischemic and hemorrhagic stroke [7, 19, 20] . Second, among the SE-related variables, only the mSTESS score emerged as an independently associated factor. Since its proposal, the status epilepticus severity score (STESS) has been widely used to estimate the prognosis in patients with SE [21] . However, this evaluation instrument has a ceiling effect in older ages, precisely the age range when PSSE most commonly occurs. For this reason, we used our proposed modification of this scale (mSTESS), which includes the patient's baseline functional status (prior to SE), estimated by the mRS. Although multicenter validation of the mSTESS must still be performed, the modified version has better prognostic value than the STESS in our experience [15] .
Regarding mortality at long-term follow-up, the 2 other factors with an impact were again the mSTESS score and the duration of SE (longer than 12 h).
Other factors related to functional impairment
The other factors having an influence on the patients' functional impairment at discharge included the duration of SE, involvement of the temporal lobe, and the patients' sex. Regarding SE duration, this finding concurs with the results of several studies showing a relationship between duration and the functional prognosis of affected patients, regardless of the SE etiology [24] [25] [26] .In our patients, SE lasting longer than 12 h was the variable most strongly related to the functional prognosis. This factor seemed more important than SE refractoriness, likely because of the definition for refractoriness established for the study.
Among the stroke-related variables, temporal lobe involvement seemed the one most strongly related to the prognosis at discharge. Most strokes in which this region was affected were middle cerebral artery ischemic infarctions or lobar hemorrhages extending to the temporal lobe, which implies a lower level of consciousness in the acute/subacute phase and greater neurological involvement (higher NIHSS score and percentage of patients with TACI syndrome). Therefore, poorer clinical status due to stroke associated with a decline in temporal lobe functions (language, cognition) in addition to the purely motor or sensory decline following SE may explain the poorer prognosis in patients with temporal lobe involvement. However, specific data on the type of sequelae remaining were not available to support this notion.
Regarding the sex-related differences in the risk of a poor functional outcome after PSSE, these are likely explained by dissimilarities in the characteristics of patients in our sample (women were older than the men and had greater comorbidity). In any case, a poorer outcome in women has been previously reported in stroke registries [27] .
This study has limitations. Although the information analyzed came from a prospective SE database, the analysis was retrospective and the data were not compared with those of stroke patients without SE to determine whether SE worsens the stroke outcome. However, our findings support that SE is, at the least, a marker of severity in a stroke patient. Another limitation is the lack of complete data on the stroke (eg, deficits, treatments, complications such as infections and fractures at short-and long-term) that could have an effect on the long-term outcome. However, again, the development of SE at different time points after a stroke seems to have different consequences regarding the outcome.
Conclusions
The time elapsed between stroke and the development of SE has different repercussions on the prognosis of patients with PSSE: shortand long-term mortality are both clearly higher when SE occurs in the first 72 h post-stroke, whereas the risk of clinical and functional decline is higher when SE occurs up to the first 3 months. Other factors, such as the mSTESS score and SE duration may be related to the prognosis not only at short-term, but also at long-term following the stroke event.
